Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus By Betty Raman, David A Bluemke, Thomas F Lüscher, Stefan Neubauer Published in: European Heart Journal DOI: 10.1093/eurheartj/ehac031 ABSTRACT Abstract CONTRIBUTOR INFORMATION Betty Raman, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK. David A. Bluemke, Department of Radiology, University of Wisconsin School of Medicine and Public Health, 3252 Clinical Science Center, 600 Highland Ave, Madison, WI 53792, USA Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 3252 Clinical Science Center, 600 Highland Ave, Madison, WI 53792, USA. Thomas F. Lüscher, Royal Brompton & Harefield Hospitals and National Heart and Lung Institute, Imperial College, London, UK Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland. Stefan Neubauer, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK. FUNDING This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and the Oxford British Heart Foundation (BHF) Centre of Research Excellence (grant number RE/18/3/34214). CONFLICT OF INTEREST B.R. has no conflict of interest related to the manuscript but has received grants from Oxford BHF CRE, NIHR Oxford Biomedical Research Centre, and UK Research and Innovation. B.R. holds US patent 16/674104. B.R. has consulted for Axcella therapeutics. S.N. reports grants from the NIHR Oxford Biomedical Research Centre and UK Research and Innovation and is a shareholder in Perspectum. S.N. was a non-executive director and consultant to Perspectum until 2019. S.N. holds US patents 61/630508 and 61-630510 licensed to Perspectum. S.N. is also a non-executive director and consultant to Caristo Diagnostics and holds two patents (one granted and one in review) on pericoronary fat assessment for risk prediction. T.F.L. has no conflicts of interest related to this manuscript but received educational and research grants from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daichi-Sankyo, Novartis, Sanofi, Servier, and Vifor outside this field. D.A.B. has no conflicts of interest related to this manuscript but has received consultant fees from Bayer. REFERENCES 1. Dong  E, Du  H, Gardner  L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis  2020;20:533–534.2. Long COVID: let patients help define long-lasting COVID symptoms. Nature  2020;586:170.3. Perego  E, Callard  F, Stras  L, Melville-Johannesson  B, Pope  R, Alwan  N. Why we need to keep using the patient made term “Long Covid”. https://blogs.bmj.com/bmj/2020/10/01/why-we-need-to-keep-using-the-patient-made-term-long-covid/ (1 October 2020).4. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. https://www.nice.org.uk/guidance/ng188 (18 December 2020).5. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (6 October 2021).6. Nalbandian  A, Sehgal  K, Gupta  A, Madhavan  MV, McGroder  C, Stevens  JS, et al.  Post-acute COVID-19 syndrome. Nat Med  2021;27:601–615.7. Al-Aly  Z, Xie  Y, Bowe  B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature  2021;594:259–264.8. Phillips  S, Williams  MA. Confronting our next national health disaster—long-haul Covid. N Engl J Med  2021;385:577–579.9. Nabavi  N. Long covid: how to define it and how to manage it. BMJ  2020;370:m3489.10. Islam  MF, Cotler  J, Jason  LA. Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue Biomed Health Behav  2020;8:61–69.11. Lyons  D, Frampton  M, Naqvi  S, Donohoe  D, Adams  G, Glynn  K. Fallout from the COVID-19 pandemic—should we prepare for a tsunami of post viral depression?  Ir J Psychol Med  2020;37:295–300.12. Hotchin  N, Read  R, Smith  D, Crawford  D. Active Epstein-Barr virus infection in post-viral fatigue syndrome. J Infect  1989;18:143–150.13. Bond  P. A role for herpes simplex virus in the aetiology of chronic fatigue syndrome and related disorders. Med Hypotheses  1993;40:301–308.14. Moldofsky  H, Patcai  J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol  2011;11:1–7.15. Carod-Artal  FJ. Post-Ebolavirus disease syndrome: what do we know?  Expert Rev Anti Infect Ther  2015;13:1185–1187.16. Sudre  CH, Murray  B, Varsavsky  T, Graham  MS, Penfold  RS, Bowyer  RC, et al.  Attributes and predictors of long COVID. Nat Med  2021;27:626–631.17. Whitaker  M, Elliott  J, Chadeau-Hyam  M, Riley  S, Darzi  A, Cooke  G, et al.  Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv  2021. doi: 10.1101/2021.06.28.2125945218. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (1 April 2021).19. Evans  RA, McAuley  H, Harrison  EM, Shikotra  A, Singapuri  A, Sereno  M, et al.  Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre prospective cohort study. Lancet Respir Med  2021;9:1275–1287.20. Augustin  M, Schommers  P, Stecher  M, Dewald  F, Gieselmann  L, Gruell  H, et al.  Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur  2021;6:100122.21. Seeßle  J, Waterboer  T, Hippchen  T, Simon  J, Kirchner  M, Lim  A, et al.  Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis  2021. doi: 10.1093/cid/ciab61122. Huang  C, Huang  L, Wang  Y, Li  X, Ren  L, Gu  X, et al.  6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet  2021;397:220–232.23. Huang  L, Yao  Q, Gu  X, Wang  Q, Ren  L, Wang  Y, et al.  1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet  2021;398:747–758.24. Dryden  M, Vika  C. Post acute sequelae of SARS-CoV-2 infection (PASC)—formally long COVID. https://www.nioh.ac.za/wp-content/uploads/2021/04/NIOH-Webinar-Invitation_-COVID-19-_Long-Covid-and-the-workplace_22-April-2021-Dr-Dryden.pdf (21 April 2021).25. Naik  S, Soneja  M, Haldar  S, Soneja  M, Mundadan  NG, Garg  P, et al.  Post COVID-19 sequelae: a prospective observational study from Northern India. Drug Discov Ther  2021;15:254–260.26. Chopra  N, Chowdhury  M, Singh  AK, Ma  K, Kumar  A, Ranjan  P, et al.  Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. Drug Discov Ther  2021;15:156–161.27. Mahmud  R, Rahman  MM, Rassel  MA, Monayem  FB, Sayeed  SJB, Islam  MS, et al.  Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh. PLoS One  2021;16:e0249644.28. Hossain  MA, Hossain  KMA, Saunders  K, Uddin  Z, Walton  LM, Raigangar  V, et al.  Prevalence of long COVID symptoms in Bangladesh: a prospective inception cohort study of COVID-19 survivors. BMJ Glob Health  2021;6:e006838.29. Lund  LC, Hallas  J, Nielsen  H, Koch  A, Mogensen  SH, Brun  NC, et al.  Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis  2021;21:1373–1382.30. Venturelli  S, Benatti  SV, Casati  M, Binda  F, Zuglian  G, Imeri  G, et al.  Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol Infect  2021;149:e32.31. Bellan  M, Soddu  D, Balbo  PE, Baricich  A, Zeppegno  P, Avanzi  GC, et al.  Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open  2021;4:e2036142.32. Logue  JK, Franko  NM, McCulloch  DJ, McDonald  D, Magedson  A, Wolf  CR, et al.  Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open  2021;4:e210830.33. Hirschtick  JL, Titus  AR, Slocum  E, Power  LE, Hirschtick  RE, Elliott  MR, et al.  Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis  2021;73:2055–2064.34. Blomberg  B, Mohn  KG-I, Brokstad  KA, Zhou  F, Linchausen  DW, Hansen  B-A, et al.  Long COVID in a prospective cohort of home-isolated patients. Nat Med  2021;27:1607–1613.35. Wu  X, Liu  X, Zhou  Y, Yu  H, Li  R, Zhan  Q, et al.  3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Resp Med  2021;9:747–754.36. Cassar  MP, Tunnicliffe  EM, Petousi  N, Lewandowski  AJ, Xie  C, Mahmod  M, et al.  Symptom persistence despite improvement in cardiopulmonary health—insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine  2021;41:101159.37. Davis  HE, Assaf  GS, McCorkell  L, Wei  H, Low  RJ, Re’em  Y, et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine  2021;38:101019.38. Thompson  EJ, Williams  DM, Walker  AJ, Mitchell  RE, Niedzwiedz  CL, Yang  TC, et al.  Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv. doi: 10.1101/2021.06.24.2125927739. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/4june2021 (4 June 2021).40. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 11 July 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1july2021 (15 August 202).41. Murray  CJ, Aravkin  AY, Zheng  P, Abbafati  C, Abbas  KM, Abbasi-Kangevari  M, et al.  Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet  2020;396:1223–1249.42. Grosso  G. Obesity during COVID-19: an underrated pandemic?  EClinicalMedicine  2021;39:101062.43. Horton  R. Offline: COVID-19 is not a pandemic. Lancet  2020;396:874.44. NHS Digital England. Health Survey for England 2019. https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019 (October 2021).45. NHS Digital England. National child measurement programme 2019. https://digital.nhs.uk/data-and-information/publications/statistical/national-child-measurement-programme/2019-20-school-year (October 2021).46. Virani  SS, Alonso  A, Aparicio  HJ, Benjamin  EJ, Bittencourt  MS, Callaway  CW, et al.  Heart disease and stroke statistics—2021 update. Circulation  2021;143:e254–e743.47. Fogarty  H, Townsend  L, Morrin  H, Ahmad  A, Comerford  C, Karampini  E, et al.  Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost  2021;19:2546–2553.48. Ritchie  S, Connell  J. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis  2007;17:319–326.49. Office of National Statistics. The prevalence of long COVID symptoms and COVID-19 complications. https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications (16 December 2020).50. Office of National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2september2021 (2 September 2021).51. Ziauddeen  N, Gurdasani  D, O’Hara  ME, Hastie  C, Roderick  P, Yao  G, et al.  Characteristics of long covid: findings from a social media survey. medRxiv  2021. doi: 10.1101/2021.03.21.2125396852. Newman  M. Chronic fatigue syndrome and long covid: moving beyond the controversy. BMJ  2021;373:n1559.53. Carfi  A, Bernabei  R, Landi  F. Persistent symptoms in patients after acute COVID-19. JAMA  2020;324:603–605.54. Carruthers  BM, van de Sande  MI, De Meirleir  KL, Klimas  NG, Broderick  G, Mitchell  T, et al.  Myalgic encephalomyelitis: international consensus criteria. J Intern Med  2011;270:327–338.55. Carruthers  BM, Jain  AK, De Meirleir  KL, Peterson  DL, Klimas  NG, Lerner  AM, et al.  Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr  2003;11:7–115.56. Singh  SJ, Barradell  AC, Greening  NJ, Bolton  C, Jenkins  G, Preston  L, et al.  British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. BMJ Open  2020;10:e040213.57. VanElzakker  MB, Brumfield  SA, Lara Mejia  PS. Neuroinflammation and cytokines in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a critical review of research methods. Front Neurol  2019;9:1033.58. Cader  S, O’Donovan  D, Shepherd  C, Chaudhuri  A. FP03-MO-02 neuropathology of post-infectious chronic fatigue syndrome. J Neurol Sci  2009;285:S60–S61.59. VanElzakker  MB. Chronic fatigue syndrome from vagus nerve infection: a psychoneuroimmunological hypothesis. Med Hypotheses  2013;81:414–423.60. Douaud  G, Lee  S, Alfaro-Almagro  F, Arthofer  C, Wang  C, McCarthy  P, et al.  Brain imaging before and after COVID-19 in UK Biobank. medRxiv  2021. doi: 10.1101/2021.06.11.2125869061. Edler  C, Schroder  AS, Aepfelbacher  M, Fitzek  A, Heinemann  A, Heinrich  F, et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med  2020;134:1275–1284.62. Basso  C, Leone  O, Rizzo  S, De Gaspari  M, van der Wal  AC, Aubry  MC, et al.  Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J  2020;41:3827–3835.63. Halushka  MK, Vander Heide  RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol  2021;50:107300.64. Aretz H  T. Myocarditis: the Dallas criteria. Hum Pathol  1987;18:619–624.65. Fox  SE, Vander Heide  RS. COVID-19: the heart of the matter—pathological changes and a proposed mechanism. J Cardiovasc Pharmacol Ther  2021;26:217–224.66. Hooper  JE, Padera  RF, Dolhnikoff  M, da Silva  LFF, Duarte-Neto  AN, Kapp  ME, et al.  A postmortem portrait of the coronavirus disease 2019 (COVID-19) pandemic: a large multi-institutional autopsy survey study. Arch Pathol Lab Med  2021;145:529–535.67. Kawakami  R, Sakamoto  A, Kawai  K, Gianatti  A, Pellegrini  D, Nasr  A, et al.  Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week. J Am Coll Cardiol  2021;77:314–325.68. Lindner  D, Fitzek  A, Bräuninger  H, Aleshcheva  G, Edler  C, Meissner  K, et al.  Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol  2020;5:1281–1285.69. Giustino  G, Croft  LB, Stefanini  GG, Bragato  R, Silbiger  JJ, Vicenzi  M, et al.  Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol  2020;76:2043–2055.70. Bois  MC, Boire  NA, Layman  AJ, Aubry  MC, Alexander  MP, Roden  AC, et al.  COVID-19-associated nonocclusive fibrin microthrombi in the heart. Circulation  2021;143:230–243.71. Vrints  CJM, Krychtiuk  KA, Van Craenenbroeck  EM, Segers  VF, Price  S, Heidbuchel  H. Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications. Acta Cardiol  2021;76:109–124.72. Robinson  FA, Mihealsick  RP, Wagener  BM, Hanna  P, Poston  MD, Efimov  IR, et al.  Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. Am J Physiol Heart Circ Physiol  2020;319:H1059–H1068.73. Yang  L, Xie  X, Tu  Z, Fu  J, Xu  D, Zhou  Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther  2021;6:255.74. Hu  Z, Li  S, Song  X. Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19. Cytokine Growth Factor Rev  2021;58:30–31.75. Pollack  A, Kontorovich  AR, Fuster  V, Dec  GW. Viral myocarditis—diagnosis, treatment options, and current controversies. Nat Rev Cardiol  2015;12:670–680.76. Kim  HW, de Chantemèle EJ  B, Weintraub  NL. Perivascular adipocytes in vascular disease. Arterioscler Thromb Vasc Biol  2019;39:2220–2227.77. Blagova  O, Varionchik  N, Zaidenov  V, Savina  P, Sarkisova  N. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol  2021;51:893–902.78. Wang  EY, Mao  T, Klein  J, Dai  Y, Huck  JD, Jaycox  JR, et al.  Diverse functional autoantibodies in patients with COVID-19. Nature  2021;595:283–288.79. Franke  C, Ferse  C, Kreye  J, Reincke  SM, Sanchez-Sendin  E, Rocco  A, et al.  High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun  2021;93:415–419.80. Richter  AG, Shields  AM, Karim  A, Birch  D, Faustini  SE, Steadman  L, et al.  Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol  2021;205:99–105.81. Konstantinov  K, Von Mikecz  A, Buchwald  D, Jones  J, Gerace  L, Tan  E. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Investig  1996;98:1888–1896.82. Loebel  M, Grabowski  P, Heidecke  H, Bauer  S, Hanitsch  LG, Wittke  K, et al.  Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun  2016;52:32–39.83. Talla  A, Vasaikar  SV, Lemos  MP, Moodie  Z, Pebworth  M-PL, Henderson  KE, et al.  Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence. bioRxiv  2021. doi: 10.1101/2021.05.26.44266684. von Meijenfeldt  FA, Havervall  S, Adelmeijer  J, Lundström  A, Magnusson  M, Mackman  N, et al.  Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv  2021;5:756–759.85. Garg  A, Goyal  S, Patel  P. A case of COVID-19 infection with delayed thromboembolic complication on warfarin. Cureus  2020;12:e8847.86. Schweblin  C, Hachulla  AL, Roffi  M, Glauser  F. Delayed manifestation of COVID-19 presenting as lower extremity multilevel arterial thrombosis: a case report. Eur Heart J Case Rep  2020;4:1–4.87. Vechi  HT, Maia  LR, MdM  A. Late acute pulmonary embolism after mild Coronavirus Disease 2019 (COVID-19): a case series. Rev Inst Med Trop Sao Paulo  2020;62:e63.88. Riyahi  S, Dev  H, Behzadi  A, Kim  J, Attari  H, Raza  SI, et al.  Pulmonary embolism in hospitalized patients with COVID-19: a multicenter study. Radiology  2021;301:E426–E433.89. Suzuki  YJ, Nikolaienko  SI, Shults  NV, Gychka  SG. COVID-19 patients may become predisposed to pulmonary arterial hypertension. Med Hypotheses  2021;147:110483.90. Ambrosino  P, Calcaterra  I, Molino  A, Moretta  P, Lupoli  R, Spedicato  GA, et al.  Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a case-control study. Biomedicines  2021;9:957.91. Ratchford  SM, Stickford  JL, Province  VM, Stute  N, Augenreich  MA, Koontz  LK, et al.  Vascular alterations among young adults with SARS-CoV-2. Am J Physiol Heart Circ Physiol  2021;320:H404–H410.92. Xiong  T-Y, Redwood  S, Prendergast  B, Chen  M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J  2020;41:1798–1800.93. Wang  D, Hu  B, Hu  C, Zhu  F, Liu  X, Zhang  J, et al.  Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA  2020;323:1061–1069.94. Shi  S, Qin  M, Shen  B, Cai  Y, Liu  T, Yang  F, et al.  Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol  2020;5:802–810.95. Lala  A, Johnson  KW, Januzzi  JL, Russak  AJ, Paranjpe  I, Richter  F, et al.  Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol  2020;76:533–546.96. Lombardi  CM, Carubelli  V, Iorio  A, Inciardi  RM, Bellasi  A, Canale  C, et al.  Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study. JAMA Cardiol  2020;5:1274–1280.97. Shi  S, Qin  M, Cai  Y, Liu  T, Shen  B, Yang  F, et al.  Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J  2020;41:2070–2079.98. Ayoubkhani  D, Khunti  K, Nafilyan  V, Maddox  T, Humberstone  B, Diamond  I, et al.  Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ  2021;372:n693.99. Daugherty  SE, Guo  Y, Heath  K, Dasmariñas  MC, Jubilo  KG, Samranvedhya  J, et al.  Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ  2021;373:n1098.100. Tazare  J, Walker  AJ, Tomlinson  L, Hickman  G, Rentsch  CT, Williamson  EJ, et al.  Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform. MedRxiv  2021. doi: 10.1101/2021.01.22.21250304101. Kotecha  T, Knight  DS, Razvi  Y, Kumar  K, Vimalesvaran  K, Thornton  G, et al.  Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J  2021;42:1866–1878.102. Clavario  P, De Marzo  V, Lotti  R, Barbara  C, Porcile  A, Russo  C, et al.  Assessment of functional capacity with cardiopulmonary exercise testing in non-severe COVID-19 patients at three months follow-up. MedRxiv  2020. doi: 10.1101/2020.11.15.20231985103. Małek  ŁA, Marczak  M, Miłosz-Wieczorek  B, Konopka  M, Braksator  W, Drygas  W, et al.  Cardiac involvement in consecutive elite athletes recovered from Covid-19: a magnetic resonance study. J Magn Reson Imaging  2021;53:1723–1729.104. Wang  H, Li  R, Zhou  Z, Jiang  H, Yan  Z, Tao  X, et al.  Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance. J Cardiovasc Magn Reson  2021;23:14.105. Vago  H, Szabo  L, Dohy  Z, Merkely  B. Cardiac magnetic resonance findings in patients recovered from COVID-19: initial experiences in elite athletes. Cardiovasc Imaging  2021;14:1279–1281.106. Mohr  A, Dannerbeck  L, Lange  TJ, Pfeifer  M, Blaas  S, Salzberger  B, et al.  Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. Multidiscip Respir Med  2021;16:732.107. Gao  Y, Chen  R, Geng  Q, Mo  X, Zhan  C, Jian  W, et al.  Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients. Eur Respir J  2021;57:2004265.108. Debeaumont  D, Boujibar  F, Ferrand-Devouge  E, Artaud-Macari  E, Tamion  F, Gravier  FE, et al.  Cardiopulmonary exercise testing to assess persistent symptoms at 6 months in people with COVID-19 who survived hospitalization: a pilot study. Phys Ther  2021;101:pzab099.109. Sonnweber  T, Sahanic  S, Pizzini  A, Luger  A, Schwabl  C, Sonnweber  B, et al.  Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J  2021;57:2003481.110. Hendrickson  BS, Stephens  RE, Chang  JV, Amburn  JM, Pierotti  LL, Johnson  JL, et al.  Cardiovascular evaluation after COVID-19 in 137 collegiate athletes: results of an algorithm-guided screening. Circulation  2021;143:1926–1928.111. Rajpal  S, Tong  MS, Borchers  J, Zareba  KM, Obarski  TP, Simonetti  OP, et al.  Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol  2021;6:116–118.112. Zhou  M, Wong  C-K, Un  K-C, Lau  Y-M, Lee  JC-Y, Tam  FC-C, et al.  Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS One  2021;16:e0246732.113. Clark  DE, Parikh  A, Dendy  JM, Diamond  AB, George-Durrett  K, Fish  FA, et al.  COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE CMR). Circulation  2021;143:609–612.114. Knight  DS, Kotecha  T, Razvi  Y, Chacko  L, Brown  JT, Jeetley  PS, et al.  COVID-19: myocardial injury in survivors. Circulation  2020;142:1120–1122.115. Rinaldo  RF, Mondoni  M, Parazzini  EM, Pitari  F, Brambilla  E, Luraschi  S, et al.  Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Respir J  2021;58:2100870.116. Catena  C, Colussi  G, Bulfone  L, Da Porto  A, Tascini  C, Sechi  LA. Echocardiographic comparison of COVID-19 patients with or without prior biochemical evidence of cardiac injury after recovery. J Am Soc Echocardiogr  2021;34:193–195.117. Starekova  J, Bluemke  DA, Bradham  WS, Eckhardt  LL, Grist  TM, Kusmirek  JE, et al.  Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol  2021;6:945–950.118. Motiejunaite  J, Balagny  P, Arnoult  F, Mangin  L, Bancal  C, d’Ortho  M-P, et al.  Hyperventilation: a possible explanation for long-lasting exercise intolerance in mild Covid-19 survivors?  Front Physiol  2021;11:1856.119. Baratto  C, Caravita  S, Faini  A, Perego  GB, Senni  M, Badano  LP, et al.  Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. J Appl Physiol  2021;130:1470–1478.120. Raman  B, Cassar  MP, Tunnicliffe  EM, Filippini  N, Griffanti  L, Alfaro-Almagro  F, et al.  Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine  2021;31:100683.121. Dennis  A, Wamil  M, Alberts  J, Oben  J, Cuthbertson  DJ, Wootton  D, et al.  Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open  2021;11:e048391.122. Puntmann  VO, Carerj  ML, Wieters  I, Fahim  M, Arendt  C, Hoffmann  J, et al.  Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol  2020;5:1265–1273.123. Ng  MY, Ferreira  VM, Leung  ST, Lee  JCY, Fong  AHT, Liu  RWT, et al.  Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging. JACC Cardiovasc Imaging  2020;13:2476–2478.124. Eiros  R, Barreiro-Perez  M, Martin-Garcia  A, Almeida  J, Villacorta  E, Perez-Pons  A, et al.  Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in health-care workers. MedRxiv  2020. doi: 10.1101/2020.07.12.20151316125. Moody  WE, Liu  B, Mahmoud-Elsayed  HM, Senior  J, Lalla  SS, Khan-Kheil  AM, et al.  Persisting adverse ventricular remodeling in COVID-19 survivors: a longitudinal echocardiographic study. J Am Soc Echocardiogr  2021;34:562–566.126. Daniels  CJ, Rajpal  S, Greenshields  JT, Rosenthal  GL, Chung  EH, Terrin  M, et al.  Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol  2021;6:1078–1087.127. Martinez  MW, Tucker  AM, Bloom  OJ, Green  G, DiFiori  JP, Solomon  G, et al.  Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. JAMA Cardiol  2021;6:745–752.128. Joy  G, Artico  J, Kurdi  H, Seraphim  A, Lau  C, Thornton  GD, et al.  Prospective case–control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc Imaging  2021;14:2155–2166.129. Moulson  N, Petek  BJ, Drezner  JA, Harmon  KG, Kliethermes  SA, Patel  MR, et al.  SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation  2021;144:256–266.130. Sechi  LA, Colussi  G, Bulfone  L, Brosolo  G, Da Porto  A, Peghin  M, et al.  Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge. Clin Res Cardiol  2021;110:1063–1072.131. de Graaf  M, Antoni  M, Ter Kuile  M, Arbous  M, Duinisveld  A, Feltkamp  M, et al.  Short-term outpatient follow-up of COVID-19 patients: a multidisciplinary approach. EClinicalMedicine  2021;32:100731.132. Daher  A, Cornelissen  C, Hartmann  N-U, Balfanz  P, Müller  A, Bergs  I, et al.  Six months follow-up of patients with invasive mechanical ventilation due to COVID-19 related ARDS. Int J Environ Res Public Health  2021;18:5861.133. Myhre  PL, Heck  SL, Skranes  JB, Prebensen  C, Jonassen  CM, Berge  T, et al.  Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity: cardiac MRI 6 months after COVID-19. Am Heart J  2021;242:61–70.134. Huang  L, Zhao  P, Tang  D, Zhu  T, Han  R, Zhan  C, et al.  Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging  2020;13:2330–2339.135. Hall  J, Myall  K, Lam  JL, Mason  T, Mukherjee  B, West  A, et al.  Identifying patients at risk of post-discharge complications related to COVID-19 infection. Thorax  2021;76:408–411.136. Li  X, Wang  H, Zhao  R, Wang  T, Zhu  Y, Qian  Y, et al.  Elevated extracellular volume fraction and reduced global longitudinal strains in patients recovered from COVID-19 without clinical cardiac findings. Radiology  2021;299:E230–E240.137. Long  B, Brady  WJ, Bridwell  RE, Ramzy  M, Montrief  T, Singh  M, et al.  Electrocardiographic manifestations of COVID-19. Am J Emerg Med  2021;41:96–103.138. Desai  AD, Boursiquot  BC, Melki  L, Wan  EY. Management of arrhythmias associated with COVID-19. Curr Cardiol Rep  2021;23:2.139. Radin  JM, Quer  G, Ramos  E, Baca-Motes  K, Gadaleta  M, Topol  EJ, et al.  Assessment of prolonged physiological and behavioral changes associated with COVID-19 infection. JAMA Network Open  2021;4:e2115959.140. Chang  TY, Chao  TF, Liu  CJ, Chen  SJ, Chung  FP, Liao  JN, et al.  The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Heart Rhythm  2016;13:1189–1194.141. Chung  MK, Martin  DO, Sprecher  D, Wazni  O, Kanderian  A, Carnes  CA, et al.  C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation  2001;104:2886–2891.142. Lakin  R, Polidovitch  N, Yang  S, Guzman  C, Gao  X, Wauchop  M, et al.  Inhibition of soluble TNFα prevents adverse atrial remodeling and atrial arrhythmia susceptibility induced in mice by endurance exercise. J Mol Cell Cardiol  2019;129:165–173.143. Hu  YF, Chen  YJ, Lin  YJ, Chen  SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol  2015;12:230–243.144. Liuba  I, Ahlmroth  H, Jonasson  L, Englund  A, Jönsson  A, Säfström  K, et al.  Source of inflammatory markers in patients with atrial fibrillation. Europace  2008;10:848–853.145. Chen  Y, Wu  S, Li  W, Wang  B, Han  X, Yang  Y, et al.  Higher high-sensitivity c reactive protein is associated with future premature ventricular contraction: a community based prospective cohort study. Sci Rep  2018;8:5152.146. Flachskampf  FA, Biering-Sørensen  T, Solomon  SD, Duvernoy  O, Bjerner  T, Smiseth  OA. Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging  2015;8:1071–1093.147. Pennell  DJ. Cardiovascular magnetic resonance. Circulation  2010;121:692–705.148. Bozkurt  B, Colvin  M, Cook  J, Cooper  LT, Deswal  A, Fonarow  GC, et al.  Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation  2016;134:e579–e646.149. Ammirati  E, Frigerio  M, Adler  ED, Basso  C, Birnie  DH, Brambatti  M, et al.  Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail  2020;13:e007405.150. Caforio  AL, Pankuweit  S, Arbustini  E, Basso  C, Gimeno-Blanes  J, Felix  SB, et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J  2013;34:2636–2648.151. Ferreira  VM, Schulz-Menger  J, Holmvang  G, Kramer  CM, Carbone  I, Sechtem  U, et al.  Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol  2018;72:3158–3176.152. Hinojar  R, Varma  N, Child  N, Goodman  B, Jabbour  A, Yu  CY, et al.  T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging  2015;8:e003285.153. Ridouani  F, Damy  T, Tacher  V, Derbel  H, Legou  F, Sifaoui  I, et al.  Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson  2018;20:58.154. Schulz-Menger  J, Bluemke  DA, Bremerich  J, Flamm  SD, Fogel  MA, Friedrich  MG, et al.  Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson  2013;15:1–19.155. Bai  W, Raman  B, Petersen  SE, Neubauer  S, Raisi-Estabragh  Z, Aung  N, et al.  Longitudinal changes of cardiac and aortic imaging phenotypes following COVID-19 in the UK biobank cohort. medRxiv  2021. doi: 10.1101/2021.11.04.21265918156. Pathik  B, Raman  B, Mohd Amin  NH, Mahadavan  D, Rajendran  S, McGavigan  AD, et al.  Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging  2016;17:1146–1152.157. Dastidar  AG, Baritussio  A, De Garate  E, Drobni  Z, Biglino  G, Singhal  P, et al.  Prognostic role of CMR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries. JACC Cardiovasc Imaging  2019;12:1973–1982.158. Assomull  RG, Lyne  JC, Keenan  N, Gulati  A, Bunce  NH, Davies  SW, et al.  The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J  2007;28:1242–1249.159. Dweck  MR, Bularga  A, Hahn  RT, Bing  R, Lee  KK, Chapman  AR, et al.  Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imaging  2020;21:949–958.160. Argulian  E, Sud  K, Vogel  B, Bohra  C, Garg  VP, Talebi  S, et al.  Right ventricular dilation in hospitalized patients with COVID-19 infection. JACC Cardiovasc Imaging  2020;13:2459–2461.161. Kim  J, Volodarskiy  A, Sultana  R, Pollie  MP, Yum  B, Nambiar  L, et al.  Prognostic utility of right ventricular remodeling over conventional risk stratification in patients with COVID-19. J Am Coll Cardiol  2020;76:1965–1977.162. Buikema  JW, Asselbergs  FW, Tekstra  J. COVID-19 related thrombi in ascending and descending thoracic aorta with peripheral embolization: a case report. Eur Heart J Case Rep  2021;5:ytaa525.163. Çora  AR, Çelik  E, Karadem  KB. Aortic thrombosis in the course of Covid-19 disease; two rare cases. Ann Vasc Surg  2021;73:119–121.164. de Carranza  M, Salazar  DE, Troya  J, Alcázar  R, Peña  C, Aragón  E, et al.  Aortic thrombus in patients with severe COVID-19: review of three cases. J Thromb Thrombolysis  2021;51:237–242.165. Oikonomou  EK, Marwan  M, Desai  MY, Mancio  J, Alashi  A, Hutt Centeno  E, et al.  Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet  2018;392:929–939.166. Elnabawi  YA, Oikonomou  EK, Dey  AK, Mancio  J, Rodante  JA, Aksentijevich  M, et al.  Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol  2019;4:885–891.167. Kotanidis  CP, Xie  C, Adlam  D, Rodrigues  JC, Siddique  M, Lockstone  H, et al.  Radiotranscriptomic analysis of perivascular adipose tissue quantifies vascular inflammation in Covid-19 from routine CT angiograms: stratification of “new UK variant” infection and prediction of in-hospital outcomes [abstract]. Heart  2021;107:A177.168. Fan  BE, Umapathi  T, Chua  K, Chia  YW, Wong  SW, Tan  GWL, et al.  Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients. J Thromb Thrombolysis  2021;51:971–977.169. Patell  R, Bogue  T, Koshy  A, Bindal  P, Merrill  M, Aird  WC, et al.  Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood  2020;136:1342–1346.170. Engelen  M, Vanassche  T, Balthazar  T, Claeys  E, Gunst  J, Jacquemin  M, et al.  Incidence of venous thromboembolism in patients discharged after COVID-19 hospitalisation [abstract]. Res Pract Thromb Haemost  2020;4:CO01.3.171. Remy-Jardin  M, Duthoit  L, Perez  T, Felloni  P, Faivre  JB, Fry  S, et al.  Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: dual-energy CT (DECT) angiographic study in 55 patients. EClinicalMedicine  2021;34:100778.172. Donna M  M, Danielle L  B, Lala  A, Trivieri Maria  G, Contreras Johanna  P, Natelson Benjamin  H. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. JACC Heart Fail  2021;9:927–937.173. Singh  I, Joseph  P, Heerdt  PM, Cullinan  M, Lutchmansingh  DD, Gulati  M, et al.  Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing. Chest  2021. doi: 10.1016/j.chest.2021.08.010174. Di Filippo  L, De Lorenzo  R, D’Amico  M, Sofia  V, Roveri  L, Mele  R, et al.  COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr  2021;40:2420–2426.175. Morley  JE, Kalantar-Zadeh  K, Anker  SD. COVID-19: a major cause of cachexia and sarcopenia?  J Cachexia Sarcopenia Muscle  2020;11:863–865.176. Dorelli  G, Braggio  M, Gabbiani  D, Busti  F, Caminati  M, Senna  G, et al.  Importance of cardiopulmonary exercise testing amongst subjects recovering from COVID-19. Diagnostics  2021;11:507.177. Johansson  M, Ståhlberg  M, Runold  M, Nygren-Bonnier  M, Nilsson  J, Olshansky  B, et al.  Long-Haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep  2021;3:573–580.178. Dani  M, Dirksen  A, Taraborrelli  P, Torocastro  M, Panagopoulos  D, Sutton  R, et al.  Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med  2021;21:e63.179. Kanjwal  K, Jamal  S, Kichloo  A, Grubb  BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J Innov Card Rhythm Manag  2020;11:4302–4304.180. Miglis  MG, Prieto  T, Shaik  R, Muppidi  S, Sinn  DI, Jaradeh  S. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res  2020;30:449–451.181. Umapathi  T, Poh  MQW, Fan  BE, Li  KFC, George  J, Tan  JYL. Acute hyperhidrosis and postural tachycardia in a COVID-19 patient. Clin Auton Res  2020;30:571–573.182. Blitshteyn  S, Whitelaw  S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res  2021;69:205–211.183. Chioh  FW, Fong  SW, Young  BE, Wu  KX, Siau  A, Krishnan  S, et al.  Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife  2021;10:e64909.184. Gavriilaki  E, Eftychidis  I, Papassotiriou  I. Update on endothelial dysfunction in COVID-19: severe disease, long COVID-19 and pediatric characteristics. J Lab Med  2021;45:293–302.185. Ho  FK, Man  KK, Toshner  M, Church  C, Celis-Morales  C, Wong  IC, et al.  Thromboembolic risk in hospitalised and non-hospitalised COVID-19 patients: a self-controlled case series analysis of a nation-wide cohort. Mayo Clin Proc  2021;96:2587–2597.186. Libby  P, Lüscher  T. COVID-19 is, in the end, an endothelial disease. Eur Heart J  2020;41:3038–3044.187. Lukose  T, De  S, Ganga  R, Ravina  M, Sahu  D, Moideen  A, et al.  Lung perfusion SPECT/CT imaging in post COVID-19 pneumonia: the spectrum of imaging findings. J Nucl Med  2021;62:2002.188. Patelli  G, Paganoni  S, Besana  F, Codazzi  F, Ronzoni  M, Manini  S, et al.  Preliminary detection of lung hypoperfusion in discharged Covid-19 patients during recovery. Eur J Radiol  2020;129:109121.189. Thornton  G, Shetye  A, Knott  K, Razvi  Y, Vimalesvaran  K, Kurdi  H, et al.  Myocardial perfusion after COVID-19 infection: no persisting impaired myocardial blood flow in surviving patients. Eur Heart J Cardiovasc Imaging  2021;22:jeab090.190. Mangion  K, Morrow  A, Bagot  C, Bayes  H, Blyth  KG, Church  C, et al.  The chief scientist office cardiovascular and pulmonary imaging in SARS coronavirus disease-19 (CISCO-19) study. Cardiovasc Res  2020;116:2185–2196.191. Tholin  B, Ghanima  W, Einvik  G, Aarli  B, Brønstad  E, Skjønsberg  OH, et al.  Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis. Br J Haematol  2021;194:542–546.192. Drake  TM, Riad  AM, Fairfield  CJ, Egan  C, Knight  SR, Pius  R, et al.  Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet  2021;398:223–237.193. Huang  C, Wang  Y, Li  X, Ren  L, Zhao  J, Hu  Y, et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet  2020;395:497–506.194. Inciardi  RM, Adamo  M, Lupi  L, Cani  DS, Di Pasquale  M, Tomasoni  D, et al.  Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J  2020;41:1821–1829.195. Alvarez-Garcia  J, Lee  S, Gupta  A, Cagliostro  M, Joshi  AA, Rivas-Lasarte  M, et al.  Prognostic impact of prior heart failure in patients hospitalized with COVID-19. J Am Coll Cardiol  2020;76:2334–2348.196. Chatrath  N, Kaza  N, Pabari  PA, Fox  K, Mayet  J, Barton  C, et al.  The effect of concomitant COVID-19 infection on outcomes in patients hospitalized with heart failure. ESC Heart Fail  2020;7:4443–4447.197. Rey  JR, Caro-Codón  J, Rosillo  SO, Iniesta  ÁM, Castrejón-Castrejón  S, Marco-Clement  I, et al.  Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail  2020;22:2205–2215.198. Halliday  BP, Wassall  R, Lota  AS, Khalique  Z, Gregson  J, Newsome  S, et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet  2019;393:61–73.199. Arrigo  M, Nijst  P, Rudiger  A. Optimising heart failure therapies in the acute setting. Card Fail Rev  2018;4:38–42.200. Sandoval  Y, Januzzi Jr  JL, Jaffe  AS. Cardiac troponin for the diagnosis and risk-stratification of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol  2020;76:1244–1258.201. Varga  Z, Flammer  AJ, Steiger  P, Haberecker  M, Andermatt  R, Zinkernagel  AS, et al.  Endothelial cell infection and endotheliitis in COVID-19. Lancet  2020;395:1417–1418.202. Evans  PC, Rainger  GE, Mason  JC, Guzik  TJ, Osto  E, Stamataki  Z, et al.  Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science. Cardiovasc Res  2020;116:2177–2184.203. Robbins-Juarez  SY, Qian  L, King  KL, Stevens  JS, Husain  SA, Radhakrishnan  J, et al.  Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep  2020;5:1149–1160.204. New  MI, Peterson  RE, Saenger  P, Levine  LS. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. J Clin Endocrinol Metab  1976;43:1283–1293.205. Dustan  HP, Bravo  EL, Tarazi  RC. Volume-dependent essential and steroid hypertension. Am J Cardiol  1973;31:606–615.206. Phelan  D, Kim  JH, Elliott  MD, Wasfy  MM, Cremer  P, Johri  AM, et al.  Screening of potential cardiac involvement in competitive athletes recovering from COVID-19. JACC Cardiovasc Imaging  2020;13:2635–2652.207. Dixit  NM, Churchill  A, Nsair  A, Hsu  JJ. Post-acute COVID-19 syndrome and the cardiovascular system: what is known?  Am Heart J Plus  2021;5:100025.208. Mitrani  RD, Dabas  N, Goldberger  JJ. COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors. Heart Rhythm  2020;17:1984–1990.209. Daynes  E, Gerlis  C, Chaplin  E, Gardiner  N, Singh  SJ. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition—a cohort study. Chron Respir Dis  2021;18:147997312110156.210. Thomas  P, Baldwin  C, Bissett  B, Boden  I, Gosselink  R, Granger  CL, et al.  Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations. J Physiother  2020;66:73–82.211. Naidu  SB, Shah  AJ, Saigal  A, Smith  C, Brill  SE, Goldring  J, et al.  The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. Eur Respir J  2021;57:2004364.212. Bhatia  RT, Marwaha  S, Malhotra  A, Iqbal  Z, Hughes  C, Börjesson  M, et al.  Exercise in the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of sports cardiology & exercise of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol  2020;27:1242–1251.213. Santos-Ferreira  D, Tomás  R, Dores  H. Return-to-play guidelines for athletes after COVID-19 infection. JAMA Cardiol  2021;6:478–479.214. Elliott  N, Martin  R, Heron  N, Elliott  J, Grimstead  D, Biswas  A. Infographic. Graduated return to play guidance following COVID-19 infection. Br J Sports Med  2020;54:1174–1175.215. Pelliccia  A, Solberg  EE, Papadakis  M, Adami  PE, Biffi  A, Caselli  S, et al.  Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J  2019;40:19–33.216. University College London. Long Covid: UCL leads £8m studies into treatments and diagnosis. https://www.ucl.ac.uk/news/headlines/2021/jul/ucl-leads-ps8m-studies-long-covid-treatments-and-diagnosis (19 July 2021).217. Collet  JP, Thiele  H, Barbato  E, Barthélémy  O, Bauersachs  J, Bhatt  DL, et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J  2021;42:1289–1367.218. Ezra A  A, Nanette K  W, Ralph G  B, Donald E  C, Theodore G  G, David R  H, et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol  2014;64:e139–e228.219. Crespo-Leiro  MG, Metra  M, Lund  LH, Milicic  D, Costanzo  MR, Filippatos  G, et al.  Advanced heart failure: a position statement of the heart failure association of the European Society of Cardiology. Eur J Heart Fail  2018;20:1505–1535.220. Yancy  CW, Jessup  M, Bozkurt  B, Butler  J, Casey  DE, Colvin  MM, et al.  2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation  2017;136:e137–e161.221. ClinicalTrials.gov. HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) (HEAL-COVID)  2021. https://clinicaltrials.gov/ct2/show/NCT04801940 (8 August 2021).222. Greenhalgh  T, Knight  M, A’Court  C, Buxton  M, Husain  L. Management of post-acute Covid-19 in primary care. BMJ  2020;370:m3026.223. Richette  P, Poitou  C, Garnero  P, Vicaut  E, Bouillot  JL, Lacorte  JM, et al.  Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis  2011;70:139–144.224. Monteiro  R, Azevedo  I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm  2010;2010:1–10.225. Koenen  M, Hill  MA, Cohen  P, Obesity  SJ. Adipose tissue and vascular dysfunction. Circ Res  2021;128:951–968.226. Knowler  WC, Barrett-Connor  E, Fowler  SE, Hamman  RF, Lachin  JM, Walker  EA, et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med  2002;346:393–403.227. Gloeckl  R, Leitl  D, Jarosch  I, Schneeberger  T, Nell  C, Stenzel  N, et al.  Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res  2021;7:00108–2021.228. Asly  M, Hazim  A. Rehabilitation of post-COVID-19 patients. Pan Afr Med J  2020;36:168.229. Jones  M, Harvey  A, Marston  L, O’Connell  NE. Breathing exercises for dysfunctional breathing/hyperventilation syndrome in adults. Cochrane Database Syst Rev  2013;5:CD009041.230. Crook  H, Raza  S, Nowell  J, Young  M, Edison  P. Long covid—mechanisms, risk factors, and management. BMJ  2021;374:n1648.231. Lord  VM, Cave  P, Hume  VJ, Flude  EJ, Evans  A, Kelly  JL, et al.  Singing teaching as a therapy for chronic respiratory disease—a randomised controlled trial and qualitative evaluation. BMC Pulm Med  2010;10:41.232. Habersaat  KB, Betsch  C, Danchin  M, Sunstein  CR, Böhm  R, Falk  A, et al.  Ten considerations for effectively managing the COVID-19 transition. Nat Hum Behav  2020;4:677–687.233. Park  CC, Chaturvedi  N, Sterne  J, Steves  C, Williams  D. Short report on long COVID. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1007511/S1327_Short_Long_COVID_report.pdf (22 July 2021).234. Arnold  AC, Okamoto  LE, Diedrich  A, Paranjape  SY, Raj  SR, Biaggioni  I, et al.  Low-dose propranolol and exercise capacity in postural tachycardia syndrome. A randomized study. Neurology  2013;80:1927–1933.235. Parsaik  A, Allison  TG, Singer  W, Sletten  DM, Joyner  MJ, Benarroch  EE, et al.  Deconditioning in patients with orthostatic intolerance. Neurology  2012;79:1435.236. Podoleanu  C, Maggi  R, Brignole  M, Croci  F, Incze  A, Solano  A, et al.  Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol  2006;48:1425–1432.237. Freeman  R, Abuzinadah  AR, Gibbons  C, Jones  P, Miglis  MG, Sinn  DI. Orthostatic hypotension. J Am Coll Cardiol  2018;72:1294–1309.238. Collaborative Group RECOVERY, Horby  P, Lim  WS, Emberson  JR, Mafham  M, Bell  JL, et al.  Dexamethasone in hospitalized patients with Covid-19. N Engl J Med  2021;384:693–704.239. Stone  JH, Frigault  MJ, Serling-Boyd  NJ, Fernandes  AD, Harvey  L, Foulkes  AS, et al.  Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med  2020;383:2333–2344.240. Beigel  JH, Tomashek  KM, Dodd  LE, Mehta  AK, Zingman  BS, Kalil  AC, et al.  Remdesivir for the treatment of Covid-19—final report. N Engl J Med  2020;383:1813–1826.241. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet  2022;399:143–151.242. Connors  JM, Brooks  MM, Sciurba  FC, Krishnan  JA, Bledsoe  JR, Kindzelski  A, et al.  Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA  2021;326:1703–1712.243. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher  EC, Bradbury  CA, McVerry  BJ, et al.  Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med  2021;385:777–789.244. Lawler  PR, Goligher  EC, Berger  JS, Neal  MD, McVerry  BJ, Nicolau  JC, et al.  Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19. N Engl J Med  2021;385:790–802.245. Lopes  RD, Furtado  RH, Macedo  AVS, Bronhara  B, Damiani  LP, Barbosa  LM, et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet  2021;397:2253–2263.246. Sadeghipour  P, Talasaz  A, Rashidi  F, Sharif-Kashani  B, Beigmohammadi  M, Farrokhpour  M, et al.  Effect of inter-mediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA  2021;325:1620–1630.247. Sholzberg  M, Tang  GH, Rahhal  H, AlHamzah  M, Kreuziger  LB, Ní Áinle  F, et al.  Heparin for moderately Ill patients with Covid-19. medRxiv  2021. doi: 10.1101/2021.07.08.21259351.248. McDonald  I, Murray  SM, Reynolds  CJ, Altmann  DM, Boyton  RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines  2021;6:74.249. Polack  FP, Thomas  SJ, Kitchin  N, Absalon  J, Gurtman  A, Lockhart  S, et al.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med  2020;383:2603–2615.250. Haas  EJ, Angulo  FJ, McLaughlin  JM, Anis  E, Singer  SR, Khan  F, et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet  2021;397:1819–1829.251. Sadoff  J, Gray  G, Vandebosch  A, Cárdenas  V, Shukarev  G, Grinsztejn  B, et al.  Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med  2021;384:2187–2201.252. Logunov  DY, Dolzhikova  IV, Shcheblyakov  DV, Tukhvatulin  AI, Zubkova  OV, Dzharullaeva  AS, et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet  2021;397:671–681.253. Tanriover  MD, Doğanay  HL, Akova  M, Güner  HR, Azap  A, Akhan  S, et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet  2021;398:213–222.254. Shinde  V, Bhikha  S, Hoosain  Z, Archary  M, Bhorat  Q, Fairlie  L, et al.  Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med  2021;384:1899–1909.255. Udell  JA, Zawi  R, Bhatt  DL, Keshtkar-Jahromi  M, Gaughran  F, Phrommintikul  A, et al.  Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA  2013;310:1711–1720.256. Johnstone  J, Loeb  M, Teo  KK, Gao  P, Dyal  L, Liu  L, et al.  Influenza vaccination and major adverse vascular events in high-risk patients. Circulation  2012;126:278–286.257. Strain  WD, Sherwood  O, Banerjee  A, Vvd  T, Hishmeh  L, Rossman  J. The impact of COVID vaccination on symptoms of long COVID. An international survey of people with lived experience of long COVID. SSRN  2021. doi: 10.2139/ssrn.3868856.258. Antonelli  M, Penfold  RS, Merino  J, Sudre  CH, Molteni  E, Berry  S, et al.  Post-vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case–control study. medRxiv  2021. doi: 10.1101/2021.05.24.21257738.259. Antonelli  M, Penfold  RS, Merino  J, Sudre  CH, Molteni  E, Berry  S, et al.  Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case–control study. Lancet Infect Dis  2022;22:43–55.260. Levine-Tiefenbrun  M, Yelin  I, Katz  R, Herzel  E, Golan  Z, Schreiber  L, et al.  Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med  2021;27:790–792.261. Murphy  J, Vallières  F, Bentall  RP, Shevlin  M, McBride  O, Hartman  TK, et al.  Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun  2021;12:1–15.262. Baden  LR, El Sahly  HM, Essink  B, Kotloff  K, Frey  S, Novak  R, et al.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med  2021;384:403–416.263. Folegatti  PM, Ewer  KJ, Aley  PK, Angus  B, Becker  S, Belij-Rammerstorfer  S, et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet  2020;396:467–478.264. Larson  KF, Ammirati  E, Adler  ED, Cooper  LT, Hong  KN, Saponara  G, et al.  Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation  2021;144:506–508.265. Kim  HW, Jenista  ER, Wendell  DC, Azevedo  CF, Campbell  MJ, Darty  SN, et al.  Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol  2021.266. Bozkurt  B, Kamat  I, Hotez  PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation  2021;144:471–484.267. Greinacher  A, Thiele  T, Warkentin  TE, Weisser  K, Kyrle  PA, Eichinger  S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med  2021;384:2092–2101.268. Munker  D, Veit  T, Barton  J, Mertsch  P, Mümmler  C, Osterman  A, et al.  Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity. Infection  2021. doi: 10.1007/s15010-021-01669-8.269. Grist  JT, Chen  M, Collier  GJ, Raman  B, AbuEid  G, McIntyre  A, et al.  Hyperpolarized 129Xe MRI abnormalities in dyspneic participants 3 months after COVID-19 pneumonia: preliminary results. Radiology  2021;301:E353–E360.270. Pretorius  E, Vlok  M, Venter  C, Bezuidenhout  JA, Laubscher  GJ, Steenkamp  J, et al.  Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol  2021;20:172.271. Pasini  E, Corsetti  G, Romano  C, Scarabelli  TM, Chen-Scarabelli  C, Saravolatz  L, et al.  Serum metabolic profile in patients with long-Covid (PASC) syndrome: clinical implications. Front Med  2021;8:714426.272. Filbin  MR, Mehta  A, Schneider  AM, Kays  KR, Guess  JR, Gentili  M, et al.  Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med  2021;2:100287.273. Giloteaux  L, Goodrich  JK, Walters  WA, Levine  SM, Ley  RE, Hanson  MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome  2016;4:30.274. Sivan  M, Rayner  C, Delaney  B. Fresh evidence of the scale and scope of long covid. BMJ  2021;373:n853.275. Norton  A, Olliaro  P, Sigfrid  L, Carson  G, Paparella  G, Hastie  C, et al.  Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. Lancet Infect Dis  2021;21:601–602.276. Abecassis  A. Five priorities for universal COVID-19 vaccination. Lancet  2021;398:285–286. ASSOCIATED DATA Supplementary Materials ehac031_Supplementary_DataClick here for additional data file.